Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada. SNMMI is the premier educational, scientific, and research event in the radiopharma space. Monopar’s poster presentation can be found at the following link: https://www.monopartx.com/pipeline/mnpr-101/snmmi-poster-june-2024.
Zebra Technologies Stock Plunges After Q2 Performance: Earnings Miss, Guidance Cut and More
Zebra Technologies Corp (NASDAQ: ZBRA) reported a second-quarter FY23 net sales decline of 17.3% year-on-year to $1.21 billion, missing the consensus of $1.31 billion.
